Age-related reduction of cerebral ischemic preconditioning: Myth or reality?

Clinical Interventions in Aging

Volumn 8, Issue , 2013, Pages 1055-1061

  Della Morte, David ^a,b   Cacciatore, Francesco ^c   Salsano, Elisa ^d   Pirozzi, Gilda ^d   del Genio, Maria Teresa ^d   D'Antonio, Iole ^d   Gaetano, Gargiulo ^e   Palmirotta, Raffaele ^b   Guadagni, Fiorella ^b   Rundek, Tatjana ^a   Abete, Pasquale ^d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c IRCCS   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e Struttura Complessa di Geriatria   (Italy)

Author keywords

Elderly; Ischemic preconditioning; Mortality; Stroke; Transient cerebral ischemic attack

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHOLIPASE C; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE C EPSILON; PROTEIN KINASE C INHIBITOR; RECOMBINANT ERYTHROPOIETIN; SIRTUIN 1; UBIQUITIN; UNCOUPLING PROTEIN 2;

AGE; AGING; AUTOPHAGY; BRAIN ISCHEMIA; BRAIN PERFUSION; CALCIUM TRANSPORT; CARDIOGENIC SHOCK; CAUSE OF DEATH; DISEASE DURATION; ENZYME RELEASE; HEART INFARCTION; HEART PROTECTION; HEART SURGERY; HEART TRANSPLANTATION; HIPPOCAMPAL CA1 REGION; HUMAN; ISCHEMIC PRECONDITIONING; LYSOSOME; MITOCHONDRIAL PERMEABILITY; MORTALITY; NEUROPROTECTION; NONHUMAN; OXYGEN CONSUMPTION; REVIEW; TRANSIENT ISCHEMIC ATTACK;

ELDERLY; ISCHEMIC PRECONDITIONING; MORTALITY; STROKE; TRANSIENT CEREBRAL ISCHEMIC ATTACK;

AGE FACTORS; AGED; ANIMALS; BRAIN; BRAIN ISCHEMIA; HUMANS; ISCHEMIC PRECONDITIONING; NEUROPROTECTIVE AGENTS;

EID: 84881265879     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S47462     Document Type: Review

References (59)

1. DeFrances CJ, Hall MJ, Podgornik MN. Advance Data From Vital and Health Statistics No 359: 2003 National Hospital Discharge Survey. Hyattsville, MD: National Center for Health Statistics; 2005. Available from: http://www.cdc.gov/nchs/data/ad/ad359.pdf. Accessed July 7, 2013.
2. Truelsen T, Piechowski-Jozwiak B, Bonita R, Mathers C, Bogousslavsky J, Boysen G. Stroke incidence and prevalence in Europe: a review of available data. Eur J Neurol. 2006;13(6):581-598.
3. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127(1):143-152.
4. Abete P, Cacciatore F, Testa G, et al. Ischemic preconditioning in the aging heart: from bench to bedside. Ageing Res Rev. 2010;9(2):153-162.
5. Comfort A. Biological theories of aging. Hum Dev. 1970;13(2): 127-139.
6. Jahangir A, Sagar S, Terzic A. Aging and cardioprotection. J Appl Physiol. 2007;103(6):2120-2128.
7. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74(5):1124-1136.
8. Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci. 2003;26(5):248-254.
9. Liu XQ, Sheng R, Qin ZH. The neuroprotective mechanism of brain ischemic preconditioning. Acta Pharmacol Sin. 2009;30(8):1071-1080.
10. Kloner RA, Bolli R, Marban E, Reinlib L, Braunwald E. Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLBI workshop. Circulation. 1998;97(18):1848-1867.
11. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003;83(4):1113-1151.
12. Przyklenk K, Whittaker P. Remote ischemic preconditioning: current knowledge, unresolved questions, and future priorities. J Cardiovasc Pharmacol Ther. 2011;16(3-4):255-259.
13. Vinten-Johansen J, Shi W. Perconditioning and postconditioning: current knowledge, knowledge gaps, barriers to adoption, and future directions. J Cardiovasc Pharmacol Ther. 2011;16(3-4):260-266.
14. Kloner RA, Shook T, Przyklenk K, et al. Previous angina alters in-hospital outcome in TIMI 4: a clinical correlate to preconditioning? Circulation. 1995;91(1):37-45.
15. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res. 2006;70(2):240-253.
16. Halestrap AP, Clarke SJ, Khaliulin I. The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Acta. 2007;1767(8):1007-1031.
17. Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation. 2008;118(19):1915-1919.
18. Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol. 2009;104(2):189-202.
19. Perez-Pinzon MA. Neuroprotective effects of ischemic preconditioning in brain mitochondria following cerebral ischemia. J Bioenerg Biomembr. 2004;36(4):323-327.
20. Kitagawa K, Matsumoto M, Tagaya M, et al. "Ischemic tolerance" phenomenon found in the brain. Brain Res. 1990;528(1):21-24.
21. Stagliano NE, Perez-Pinzon MA, Moskowitz MA, Huang PL. Focal ischemic preconditioning induces rapid tolerance to middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab. 1999;19(7):757-761.
22. Nishi S, Taki W, Uemura Y, et al. Ischemic tolerance due to the induction of HSP70in a rat ischemic recirculation model. Brain Res. 1993;615(2):281-288.
23. Dave KR, Saul I, Busto R, Ginsberg MD, Sick TJ, Perez-Pinzon MA. Ischemic preconditioning preserves mitochondrial function after global cerebral ischemia in rat hippocampus. J Cereb Blood Flow Metab. 2001;21(12):1401-1410.
24. Chen Y, Ruetzler C, Pandipati S, et al. Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury. Proc Natl Acad Sci U S A. 2003;100(25):15107-15112.
25. Gesuete R, Orsini F, Zanier ER, et al. Glial cells drive preconditioning-induced blood-brain barrier protection. Stroke. 2011;42(5):1445-1453.
26. Grabb MC, Choi DW. Ischemic tolerance in murine cortical cell culture: critical role for NMDA receptors. J Neurosci. 1999;19(5): 1657-1662.
27. Blondeau N, Widmann C, Lazdunski M, Heurteaux C. Activation of the nuclear factor-κB is a key event in brain tolerance. J Neurosci. 2001;21(13):4668-4677.
28. Andjelkovic AV, Stamatovic SM, Keep RF. The protective effects of preconditioning on cerebral endothelial cells in vitro. J Cereb Blood Flow Metab. 2003;23(11):1348-1355.
29. Xu GP, Dave KR, Vivero R, Schmidt-Kastner R, Sick TJ, Perez-Pinzon MA. Improvement in neuronal survival after ischemic preconditioning in hippocampal slice cultures. Brain Res. 2002;952(2): 153-158.
30. Chan MT, Boet R, Ng SC, Poon WS, Gin T. Effect of ischemic preconditioning on brain tissue gases and pH during temporary cerebral artery occlusion. Acta Neurochir Suppl. 2005;95:93-96.
31. Bond A, Lodge D, Hicks CA, Ward MA, O'Neill MJ. NMDA receptor antagonism, but not AMPA receptor antagonism attenuates induced ischemic tolerance in the gerbil hippocampus. Eur J Pharmacol. 1999;380(2-3):91-99.
32. Weih M, Kallenberg K, Bergk A, et al. Attenuated stroke severity after prodromal TIA: a role for ischemic tolerance in the brain? Stroke. 1999;30(9):1851-1854.
33. Moncayo J, de Freitas GR, Bogousslavsky J, Altieri M, van Melle G. Do transient ischemic attacks have a neuroprotective effect? Neurology. 2000;54(11):2089-2094.
34. Castillo J, Moro MA, Blanco M, et al. The release of tumor necrosis factor-α is associated with ischemic tolerance in human stroke. Ann Neurol. 2003;54(6):811-819.
35. Wegener S, Gottschalk B, Jovanovic V, et al; MRI in Acute Stroke Study Group of the German Competence Network Stroke. Transient ischemic attacks before ischemic stroke: preconditioning the human brain? A multicenter magnetic resonance imaging study. Stroke. 2004;35(3):616-621.
36. Arboix A, Cabeza N, Garcia-Eroles L, et al. Relevance of transient ischemic attack to early neurological recovery after nonlacunar ischemic stroke. Cerebrovasc Dis. 2004;18(4):304-311.
37. Galizia G, Abete P, Mussi C, et al. Role of early symptoms in assessment of syncope in elderly people: results from the Italian group for the study of syncope in the elderly. J Am Geriatr Soc. 2009;57(1):18-23.
38. Schaller B. Ischemic preconditioning as induction of ischemic tolerance after transient ischemic attacks in human brain: its clinical relevance. Neurosci Lett. 2005;377(3):206-211.
39. Johnston SC. Ischemic preconditioning from transient ischemic attacks? Data from the Northern California TIA Study. Stroke. 2004;35(11 Suppl 1):2680-2682.
40. Abete P, Ferrara N, Cacciatore F, et al. High level of physical activity preserves the cardioprotective effect of preinfarction angina in elderly patients. J Am Coll Cardiol. 2001;38(5):1357-1365.
41. Perez-Pinzon MA. Mechanisms of neuroprotection during ischemic preconditioning: lessons from anoxic tolerance. Comp Biochem Physiol A Mol Integr Physiol. 2007;147(2):291-299.
42. Della-Morte D, Caso V, Guadagni F. A continuous debate about cerebral ischemic preconditioning in the elderly. J Neurol Neurophysiol. 2011;2:101e.
43. Dowden J, Corbett D. Ischemic preconditioning in 18-to 20-month-old gerbils: long-term survival with functional outcome measures. Stroke. 1999;30(6):1240-1246.
44. He Z, Crook JE, Meschia JF, Brott TJ, Dickson DW, McKinney M. Aging blunts ischemic preconditioning-induced neuroprotection following transient global ischemia in rats. Curr Neurovasc Res. 2005;2(5):365-374.
45. Schaller B, Graf R. Cerebral ischemic preconditioning. An experimental phenomenon or a clinical important entity of stroke prevention? J Neurol. 2002;249(11):1503-1511.
46. Kitagawa K. Ischemic tolerance in the brain: endogenous adaptive machinery against ischemic stress. J Neurosci Res. 2012;90(5): 1043-1054.
47. Della-Morte D, Abete P, Gallucci F, et al. Transient ischemic attack before nonlacunar ischemic stroke in the elderly. J Stroke Cerebrovasc Dis. 2008;17(5):257-262.
48. Shankar SK. Biology of aging brain. Indian J Pathol Microbiol. 2010;53(4):595-604.
49. Budas GR, Churchill EN, Mochly-Rosen D. Cardioprotective mechanisms of PKC isozyme-selective activators and inhibitors in the treatment of ischemia-reperfusion injury. Pharmacol Res. 2007;55(6): 523-536.
50. Della-Morte D, Guadagni F, Palmirotta R, et al. Genetics of ischemic stroke, stroke-related risk factors, stroke precursors and treatments. Pharmacogenomics. 2012;13(5):595-613.
51. Koch S, Sacco RL, Perez-Pinzon MA. Preconditioning the brain: moving on to the next frontier of neurotherapeutics. Stroke. 2012;43(6): 1455-1457.
52. Della-Morte D, Raval AP, Dave KR, Lin HW, Perez-Pinzon MA. Post-ischemic activation of protein kinase C ε protects the hippocampus from cerebral ischemic injury via alterations in cerebral blood flow. Neurosci Lett. 2012;487(2):158-162.
53. Lin HW, Della-Morte D, Thompson JW, et al. Differential effects of δ and ε protein kinase C in modulation of postischemic cerebral blood flow. Adv Exp Med Biol. 2012;737:63-69.
54. Della-Morte D, Dave KR, DeFazio RA, Bao YC, Raval AP, Perez-Pinzon MA. Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience. 2009;159(3):993-1002.
55. Ehrenreich H, Weissenborn K, Prange H, et al; EPO Stroke Trial Group. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40(12):e647-e656.
56. Walsh SR, Nouraei SA, Tang TY, Sadat U, Carpenter RH, Gaunt ME. Remote ischemic preconditioning for cerebral and cardiac protection during carotid endarterectomy: results from a pilot randomized clinical trial. Vasc Endovascular Surg. 2010;44(6):434-439.
57. Koch S, Katsnelson M, Dong C, Perez-Pinzon M. Remote ischemic limb preconditioning after subarachnoid hemorrhage: a Phase Ib study of safety and feasibility. Stroke. 2011;42(5):1387-1391.
58. Lefer DJ, Bolli R. Development of an NIH Consortium for Preclinical Assessment of Cardioprotective Therapies (CAESAR): a paradigm shift in studies of infarct size limitation. J Cardiovasc Pharmacol Ther. 2011;16(3-4):332-339.
59. Abete P, Testa G, Della-Morte D, et al. Treatment for chronic heart failure in the elderly: current practice and problems. Heart Fail Rev. 2013;18(4):529-51.